|drug787||Clinical interview Wiki||1.00|
|drug471||Blood collection Wiki||1.00|
|drug2998||Saliva collection Wiki||0.41|
There is one clinical trial.
This is a pilot feasibility study of remotely delivered Problem Management Plus, a low-intensity psychological intervention, delivered in five sessions to adults affected by crisis. The current study will evaluate the feasibility and acceptability of the intervention when delivered remotely via Zoom to community members in New York City impacted by the COVID-19 pandemic. The investigator's goal is to use qualitative and quantitative approaches to inform procedures for a subsequent cluster randomized control trial of Problem Management Plus versus enhanced usual care. A mixed-methods design will be used to evaluate the feasibility, acceptability, perceived utility, and impact of the remotely delivered PM+ intervention, to determine recruitment and retention rates, to assess ethics and safety of trial procedures. Additionally, the study will evaluate the acceptability, feasibility and fidelity of the remote training and supervision of helpers trained to deliver the intervention.
Description: 4-item measure of personalized distress and client-generated problems, function and wellbeing; minimum value = 0, maximum value = 20; higher scores mean greater distressMeasure: Psychological Outcomes Profile; Unabbreviated scale title "Psychological Outcomes Profile" Time: 1 week post-intervention
Description: 9-item measure of depression symptoms; minimum value = 0, maximum value = 27; higher scores mean more severe depression symptomsMeasure: Patient Health Questionnaire; Unabbreviated scale title "Patient Health Questionnaire" Time: 1 week post-intervention
Description: 7-item measure of anxiety symptoms; minimum value = 0 and maximum value = 21; higher scores mean more severe anxiety symptomsMeasure: Generalized Anxiety Disorder Scale; Unabbreviated scale title "Generalized Anxiety Disorder 7-item Scale" Time: 1 week post-intervention
Description: 12-item measure of ability to engage in daily activities and functioning; minimum value = 0, maximum value = 48; higher scores mean worse disability outcomesMeasure: World Health Organization Disability Assessment Scale 2.0; Unabbreviated scale title "World Health Organization Disability Assessment Scale 2.0" Time: 1 week post-intervention
Description: 26-item quality of life assessment of physical health, psychological health, social, relationships and environment; minimum value = 26 and maximum value = 130; higher scores mean better quality of lifeMeasure: World Health Organization Quality of Life Questionnaire-BREF; Unabbreviated scale title "World Health Organization Quality of Life Questionnaire-BREF" Time: 1 week post-intervention
Description: 5-item assessment of dimensions of health status: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; minimum= 5, maximum = 25; higher score mean worse health outcomesMeasure: EuroQoL 5-dimension 5-level; Unabbreviated scale title "EuroQoL 5-dimension 5-level" Time: 1 week post-intervention
Description: 19-item measure of sleep quality and disturbance; 19 items combined to form 7 "component" scores, each of which has a range of 0-3 points, 7 component scores are added to yield one global global score; minimum value = 0 and maximum value = 21; higher score means greater difficulty sleepingMeasure: Pittsburgh Sleep Quality Index; Unabbreviated scale title "Pittsburgh Sleep Quality Index" Time: 1 week post-intervention
Description: 8-item assessment of the presence and severity of common somatic symptoms; minimum value = 0, maximum value = 32; higher score means more severe somatic symptomsMeasure: Somatic Symptom Scale-8; Unabbreviated scale title "Somatic Symptom Scale-8" Time: 1 week post-intervention
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports